Skip to main content
S&P 5007,607.35+0.29%DOW52,005.66-0.17%NASDAQ26,151.86+0.66%BTC$75,639.00-0.14%ETH$2,387.43-0.87%GOLD$4,382.80+1.15%OIL$103.20-2.49%
Smart Investors Daily
UN

NASDAQ · UNCY

Unicycive Therapeutics, Inc.

Healthcare · Biotechnology

$4.71

Up+$0.06 (+1.27%)

Updated Sep 16, 2026, 2:09 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
113.26M
P/E ratio
-3.47
Dividend yield
0.00%
52-week range
$3.93 – $8.74
Volume
1.69M
Avg. volume
458.61K

Price performance

UNCY price history

1M range · 20 trading sessions · Daily adjusted prices

UNCY closed at $4.71 after 20 trading sessions, down 16.34% for the selected period.

Last close
$4.71
Period change
-16.34%
Period low
$4.71
Period high
$5.63
Daily close
View OHLC price history
UNCY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$5.15$5.15$4.71$4.711.69M
Sep 14, 2026$5.27$5.35$5.13$5.15671K
Sep 11, 2026$5.34$5.40$5.22$5.291.12M
Sep 10, 2026$5.07$5.62$5.04$5.311.24M
Sep 9, 2026$5.03$5.14$5.01$5.12906.97K
Sep 8, 2026$5.13$5.2199$5.025$5.03817.18K
Sep 4, 2026$5.24$5.24$5.12$5.16492.88K
Sep 3, 2026$5.20$5.34$5.08$5.30836.93K
Sep 2, 2026$5.10$5.22$5.06$5.19760.47K
Sep 1, 2026$5.13$5.21$5.04$5.05673.45K
Aug 31, 2026$5.27$5.27$5.13$5.20578.04K
Aug 28, 2026$5.50$5.50$5.26$5.265609.26K
Aug 27, 2026$5.43$5.515$5.42$5.50366.16K
Aug 26, 2026$5.46$5.55$5.35$5.43906.2K
Aug 25, 2026$5.40$5.52$5.32$5.47417.05K
Aug 24, 2026$5.64$5.64$5.26$5.34742.96K
Aug 21, 2026$5.51$5.77$5.50$5.631.01M
Aug 20, 2026$5.60$5.68$5.4101$5.45643.26K
Aug 19, 2026$5.75$5.7904$5.54$5.58845.89K
Aug 18, 2026$5.57$5.85$5.56$5.63738.9K

Latest UNCY news

The latest Smart Investors Daily articles mentioning UNCY.

Stock researchCompany · Overview

UNCY research

Overview

Company profile and research snapshot.

Company profile

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
UNCY recent ratings
DateFirmRatingTarget
Aug 20, 2026BenchmarkSpeculative Buy—
Aug 13, 2026GuggenheimBuy—
Aug 13, 2026B. Riley SecuritiesBuy—
Jul 1, 2026BenchmarkSpeculative Buy—
Jul 1, 2026Noble Capital MarketsOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website unde

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By